The Science

Sildenafil's Other Job: Treating Newborns With Pulmonary Hypertension

The same molecule in Sildatron-100 has a second, far more serious life in neonatal intensive care — and the real story is more complicated than a headline.

The Science, Explained · 6 min read

Sildenafil's fame is entirely about erectile function, but the drug's actual pharmacology has nothing inherently to do with sex — it relaxes smooth muscle in blood vessels by blocking an enzyme called PDE5. That mechanism turns out to matter in a completely different, much higher-stakes setting: the lungs of critically ill newborns.

What persistent pulmonary hypertension of the newborn actually is

Persistent pulmonary hypertension of the newborn, or PPHN, happens when a baby's circulatory system fails to make the normal transition at birth — pressure in the lung's blood vessels stays abnormally high, blood gets shunted away from the lungs, and the baby can't oxygenate properly. It's serious, with mortality historically cited in the range of 10–20% in affected infants, and it requires intensive care.

Where sildenafil actually fits in

Inhaled nitric oxide is the treatment approved by U.S. and EU regulators for PPHN. Sildenafil works through a related pathway — it inhibits the enzyme that breaks down cyclic GMP, extending the same relaxing effect on pulmonary blood vessels that nitric oxide triggers directly. Multiple clinical trials have found sildenafil improves oxygenation in PPHN, and it has become a genuinely useful option specifically in settings where iNO isn't available or hasn't worked — including many hospitals in lower-resource countries where the specialized equipment for inhaled nitric oxide simply isn't accessible.

This use is largely off-label for the acute newborn setting — sildenafil for PPHN in neonates isn't the same as an FDA-approved, on-label indication the way iNO is. Case reports and smaller trials, including compounded oral formulations used specifically because IV or inhaled options weren't available, describe it as an effective alternative or adjunct rather than a first-line replacement.

The warning worth knowing about

This is the part that keeps this from being a simple good-news story. The FDA has issued a specific warning against long-term, high-dose sildenafil use in pediatric pulmonary hypertension for children aged 1–17, after data suggested an increased mortality signal with chronic high-dose therapy in that older pediatric population. That warning is about long-term treatment in older children with chronic pulmonary hypertension — a different clinical scenario from short-term sildenafil use in acute newborn PPHN — but it's the reason this isn't a story about an uncomplicated miracle drug. Researchers reviewing the evidence have explicitly called for more study of sildenafil's safety, especially with longer courses of treatment.